pedro coelho

Biorce's AI operating system automates the clinical trial protocol lifecycle — from molecule viability simulation to protocol generation to study design optimization — reducing the median $6B/12-year drug development process by 50% in time and cost. Early customers show 600K EUR savings per trial on protocol alone.

Large pharma companies are signing multi-year contracts (70% 3-year, now piloting 5-year) for Biorce's platform at 250K-10M+ EUR base subscriptions plus usage fees. The buying trigger is regulatory pressure (EMA/FDA) and patent clock economics: arriving 1 year earlier to market on a $2B/year drug justifies 200M+ trial spend acceleration.

Biorce's 'true agentic workforce' coordinates specialized agents for protocol generation, study design, patient simulation, regulatory strategy, and economic optimization. Currently replaces ~50% of CRO work (documentation, process management); full autonomy awaits regulatory acceptance of AI-to-AI submission/review. The $120B CRO market is the addressable opportunity.

Biorce built a model orchestrator that decomposes clinical trial workflows into discrete tasks (protocol writing, statistical analysis, 3D molecule visualization, regulatory compliance) and routes each to the optimal model — proprietary fine-tuned models for domain reasoning, Anthropic/Google for math/coding — maintaining chain-of-thought consistency across the workflow.

Biorce's AI platform trained on 1M+ clinical trials automates protocol drafting (90 seconds vs 8 months), hospital selection, and contract negotiation, targeting the 40% 'white space' between trial phases. This could compress 12-year drug development to 6 years.

Biorce deploys dedicated Kubernetes clusters in each client's cloud account (AWS/Azure/GCP) with a 'data lakehouse' architecture (Databricks/Snowflake) where model updates are pushed but data never pulled. This satisfies pharma's requirement that proprietary trial data never leaves their controlled environment while enabling continuous model improvement.

Biorce's pricing formula (based on trial count, molecules, headcount) yields 250K-10M+ EUR base ARR per client with usage overages. At 150 trials/year for large pharma, this scales to 100M+ EUR accounts. The model captures value from both time savings (50% faster trials) and cost reduction (50-70% cheaper protocols) vs traditional CROs.

European pharma buyers require Business Continuity Plans (3-5 year runway) and auditability of AI training data flows. Biorce's single-tenant architecture with auditor-accessible training logs and push-only model updates positions them ahead of EU AI Act compliance. Open Evidence's EU blocking illustrates regulatory risk for non-compliant clinical AI.